United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says

MT Newswires Live

02/27

United Therapeutics' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.

The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.

The "surprise announcement" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.

SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.

RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.

Price: 498.49, Change: -36.62, Percent Change: -6.84

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2614247500"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614247500\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614247500?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-27 01:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614247500","market":"us","top_or_hot":-1,"title":"United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says","media":"MT Newswires Live","content":"<html><body><p> United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.</p><p>The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.</p><p>The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.</p><p>SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.</p><p>RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.</p><p>Price: 498.49, Change: -36.62, Percent Change: -6.84</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Therapeutics' Soft-Mist Inhaler for Tyvaso Could Boost Market Share, RBC Says\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-02-27 01:13</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.</p><p>The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.</p><p>The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.</p><p>SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.</p><p>RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.</p><p>Price: 498.49, Change: -36.62, Percent Change: -6.84</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1699723380.USD","symbol_name":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2614247500","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2614247500","pubTimestamp":1772125988,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"United Therapeutics'  development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.RBC raised its price target on United Therapeutics to $643 from ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","BK4532":"文艺复兴科技持仓","BK4139":"生物科技","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","UTHR":"美国联合医疗"},"translate_title":"加拿大皇家银行表示，United Therapeutics的Tyvaso软雾吸入器可能会提高市场份额","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1.5},"content_text":"United Therapeutics' (UTHR) development of a soft-mist inhaler for treprostinil or Tyvaso could boost the company's market share as the future of Tyvaso dry powder inhaler remains unclear, RBC Capital Markets said Wednesday.The company reported Q4 earnings of $7.70 per diluted share, up from $6.19 a year earlier, as revenue increased to $790.2 million from $735.9 million. RBC said Q4 revenue from both the Tyvaso franchise and Tyvaso dry powder inhaler, or DPI, missed market expectations.The \"surprise announcement\" of the soft-mist inhaler or SMI is a positive and could improve the profile of the company's inhaled Tyvaso franchise versus competitors, according to RBC. United Therapeutics claimed that the SMI could reduce cough and improve convenience, while maintaining efficacy, RBC noted.SMI remains under development and United Therapeutics expects to complete filings this year for a potential launch in 2027, the brokerage said.RBC raised its price target on United Therapeutics to $643 from $587, with an outperform rating.Price: 498.49, Change: -36.62, Percent Change: -6.84","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}